Vident Advisory’s Amylyx Pharmaceuticals AMLX Stock Holding History

Vident Advisory’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,862	Closed	-$41.1K	–	1554
2024 Q4	$41.1K	Sell	10,862 -4,710	-30%	-$22.2K	﹤0.01%	1427
2024 Q3	$50.5K	Buy	15,572 +4,729	+44%	+$10.6K	﹤0.01%	1400
2024 Q2	$20.6K	Buy	+10,843	New	+$21K	﹤0.01%	1403

Other funds holding AMLX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vident Advisory's AMLX Position: Q1 2025 in Review

Vident Advisory sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2025, closing a stake of 10,862 shares — an estimated $41.1K sold.

Vident Advisory first reported a position in AMLX in Q2 2024 and held it in 3 quarters. The position peaked at $50.5K in Q3 2024. 136 funds tracked by Wall St. Rank hold AMLX as of Q1 2025.

Vident Advisory reported no remaining Amylyx Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Vident Advisory sold 10,862 Amylyx Pharmaceuticals shares in Q1 2025, an estimated $41.1K.
Vident Advisory first reported a position in Amylyx Pharmaceuticals in Q2 2024 and held it in 3 quarters.
Vident Advisory's Amylyx Pharmaceuticals position peaked at $50.5K in Q3 2024.
136 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2025.

Based on Vident Advisory's 13F filing for Q1 2025, filed 15 May 2025.